NBIX Stock Analysis: Buy, Sell, or Hold?
NBIX - Neurocrine Biosciences Inc
$153.04
0.47 (0.31%)
▲
5d:
-0.94%
30d:
-12.93%
90d:
-2.34%
HOLD
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When NBIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NBIX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NBIX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$270.41
Based on 10.7% avg growth
INTRINSIC VALUE TODAY
$167.90
8.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NBIX is currently trading at $153.04, which is considered oversold relative to its 30-day fair value range of $156.87 to $176.55. The stock's valuation (Forward PE: 12.8) is in line with its historical norms (13.7). Remarkably, the market is currently pricing in an annual earnings decline of 2.4% over the next few years. This pessimistic expectation contrasts with the company's recent 31.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NBIX is in a strong uptrend. The price is currently testing key support at $148.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NBIX scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $211.57 (+38.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NBIX is in a strong uptrend. The price is currently testing key support at $148.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NBIX scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $211.57 (+38.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$156.87 -
$176.55
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding NBIX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.7% below Wall St target ($211.57)
- CAUTION: Bottoming setup, but lagging the sector by 13% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$156.87 -
$176.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$148.78
Resistance Level
$165.46
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.76
Wall Street Target
$211.57
(+38.7%)
Revenue Growth (YoY)
39.5%
Earnings Growth (YoY)
31.1%
Profit Margin
20.9%
Valuation Discount vs History
-2.4% cheaper
PE vs Historical
12.8 vs 13.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.4%
(market-implied from PE analysis)
1-Year Target
$148.91
(-2%)
2-Year Target
$145.33
(-5%)
3-Year Target
$141.85
(-7%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$152.26
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 17.3%)
$387.44
(+154%)
Base:
(SPY PE: 12.8, Growth: 17.3%)
$246.39
(+62%)
Bear:
(PE: 10.8, Growth: 17.3%)
$209.43
(+37%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 22.72 | Current EPS (TTM): $6.73
Bull Case
$298.79
(+96%)
Analyst growth 77.6%, PE expands to 25.0
Base Case
$271.63
(+78%)
Market implied 77.6%, PE stable at 22.7
Bear Case
$103.99
(-32%)
Severe decline -20.0%, PE contracts to 19.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.8 to 13.7
Stabilization Target:
$163.77
(+7.3%)
PE Expansion Potential:
+7.3%
Share & Embed Analysis
Last updated: August 24, 2026 4:40 PM ET
Data refreshes hourly during market hours. Next update: 5:40 PM
Data refreshes hourly during market hours. Next update: 5:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 59 HOLD |
Advanced NBIX Option Strategies
Professional options setups generated by AI based on today's NBIX price and gamma walls.
